The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparing myeloablative and reduced-intensity conditioning for allogeneic PBSCT in MDS with increased blasts.
 
Bana Antonios
No Relationships to Disclose
 
Asmi Chattaraj
No Relationships to Disclose
 
Eiraj Khan
No Relationships to Disclose
 
Gina Patrus
No Relationships to Disclose
 
Cyrus Khan
Speakers' Bureau - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb; Kite, a Gilead company; Lilly; Roche; Seagen
Research Funding - BeiGene (Inst); Roche (Inst)
 
Yazan Samhouri
Consulting or Advisory Role - Abbvie; ADC Therapeutics; BeiGene; Epizyme; Genentech
 
Santhosh Sadashiv
Consulting or Advisory Role - Janssen Biotech
 
Prerna Mewawalla
Consulting or Advisory Role - Johnson & Johnson/Janssen; Pfizer
 
Anna Koget
Consulting or Advisory Role - BMS
 
John Lister
Consulting or Advisory Role - Oncology Analytics
 
Salman Fazal
Honoraria - Agios; Amgen; Blueprint Medicines; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Incyte; Janssen Oncology; Jazz Pharmaceuticals; Karyopharm Therapeutics; Novartis; Pharmaessentia; Rigel; Sanofi; SERVIER; SOBI; Stemline Therapeutics; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Agios; Amgen; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Incyte; Janssen Oncology; Jazz Pharmaceuticals; Karyopharm Therapeutics; Novartis; Sanofi/Aventis; Sanofi/Aventis; SOBI; Stemline Therapeutics; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Agios; Amgen; Blueprint Medicines; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Incyte; Janssen Oncology; Jazz Pharmaceuticals; Karyopharm Therapeutics; Novartis; Pharmaessentia; Sanofi/Aventis; SOBI; Stemline Therapeutics; Taiho Pharmaceutical; Takeda
Travel, Accommodations, Expenses - Agios; Amgen; Blueprint Medicines; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Incyte; Janssen Oncology; Jazz Pharmaceuticals; Karyopharm Therapeutics; Novartis; Pharmaessentia; Sanofi/Aventis; SOBI; Stemline Therapeutics; Taiho Oncology; Takeda